Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GHNYSE:HIMSNASDAQ:NTRANASDAQ:OPCH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGHGuardant Health$49.99+3.0%$44.62$20.14▼$52.92$6.01B1.372.13 million shs1.59 million shsHIMSHims & Hers Health$42.98+2.4%$48.98$13.47▼$72.98$9.40B2.0922.34 million shs63.30 million shsNTRANatera$171.87+0.9%$157.84$92.14▼$183.00$23.26B1.741.41 million shs935,378 shsOPCHOption Care Health$32.26+3.9%$32.06$21.39▼$35.53$5.08B0.741.87 million shs1.29 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGHGuardant Health+2.97%+0.93%+31.55%+9.05%+71.85%HIMSHims & Hers Health+2.12%-27.36%-21.69%+28.71%+94.14%NTRANatera+0.88%+2.58%+12.10%+14.70%+60.01%OPCHOption Care Health+3.90%+1.32%+2.71%-7.91%+12.56%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGHGuardant Health3.6847 of 5 stars2.53.00.04.31.52.50.6HIMSHims & Hers Health2.4391 of 5 stars2.03.00.00.01.83.31.9NTRANatera1.1856 of 5 stars1.52.00.00.03.12.50.6OPCHOption Care Health3.7696 of 5 stars2.43.00.04.23.11.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGHGuardant Health 3.00Buy$53.767.55% UpsideHIMSHims & Hers Health 2.00Hold$38.00-11.59% DownsideNTRANatera 3.00Buy$184.637.42% UpsideOPCHOption Care Health 2.88Moderate Buy$35.5010.04% UpsideCurrent Analyst Ratings BreakdownLatest HIMS, NTRA, GH, and OPCH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/23/2025HIMSHims & Hers HealthNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold6/18/2025OPCHOption Care HealthJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$36.006/13/2025GHGuardant HealthMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$60.00 ➝ $65.006/11/2025HIMSHims & Hers HealthMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingEqual Weight ➝ Equal Weight$40.006/4/2025HIMSHims & Hers HealthNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$61.00 ➝ $65.005/15/2025NTRANateraPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$205.00 ➝ $210.005/9/2025NTRANateraUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$211.00 ➝ $218.005/9/2025NTRANateraBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$160.00 ➝ $190.005/7/2025HIMSHims & Hers HealthDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold5/6/2025HIMSHims & Hers HealthUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMixed ➝ Mixed5/6/2025GHGuardant HealthPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$50.00 ➝ $60.00(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGHGuardant Health$739.02M8.38N/AN/A($1.13) per share-44.24HIMSHims & Hers Health$1.48B6.52$0.36 per share119.21$2.16 per share19.90NTRANatera$1.70B13.83N/AN/A$9.05 per share18.99OPCHOption Care Health$5.00B1.06$1.71 per share18.88$8.25 per share3.91Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGHGuardant Health-$436.37M-$3.39N/AN/AN/A-53.82%-1,200.44%-26.77%8/6/2025 (Estimated)HIMSHims & Hers Health$126.04M$0.6962.3082.661.589.24%22.75%15.51%8/4/2025 (Estimated)NTRANatera-$190.43M-$1.47N/AN/AN/A-10.36%-18.29%-11.68%8/14/2025 (Estimated)OPCHOption Care Health$211.82M$1.2426.0225.601.884.12%16.90%7.00%7/30/2025 (Estimated)Latest HIMS, NTRA, GH, and OPCH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025NTRANatera-$0.59-$0.50+$0.09-$0.50$446.68 million$501.83 million5/5/2025Q1 2025HIMSHims & Hers Health$0.12$0.20+$0.08$0.20$535.21 million$586.01 million4/30/2025Q1 2025GHGuardant Health-$0.57-$0.49+$0.08-$0.77$189.91 million$203.47 million4/29/2025Q1 2025OPCHOption Care Health$0.36$0.40+$0.04$0.28$1.26 billion$1.33 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGHGuardant HealthN/AN/AN/AN/AN/AHIMSHims & Hers HealthN/AN/AN/AN/AN/ANTRANateraN/AN/AN/AN/AN/AOPCHOption Care HealthN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGHGuardant HealthN/A4.113.76HIMSHims & Hers HealthN/A1.591.32NTRANateraN/A3.873.74OPCHOption Care Health0.821.541.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGHGuardant Health92.60%HIMSHims & Hers Health63.52%NTRANatera99.90%OPCHOption Care Health98.05%Insider OwnershipCompanyInsider OwnershipGHGuardant Health6.10%HIMSHims & Hers Health17.71%NTRANatera7.60%OPCHOption Care Health0.64%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGHGuardant Health2,021123.89 million116.33 millionNot OptionableHIMSHims & Hers Health1,637223.83 million184.19 millionOptionableNTRANatera4,434136.55 million126.17 millionOptionableOPCHOption Care Health8,088163.75 million162.70 millionOptionableHIMS, NTRA, GH, and OPCH HeadlinesRecent News About These CompaniesOption Care Health’s Q1 Earnings Call: Our Top 5 Analyst QuestionsJune 23 at 7:39 AM | finance.yahoo.comOption Care Health, Inc. (NASDAQ:OPCH) Shares Sold by Avior Wealth Management LLCJune 22 at 4:22 AM | marketbeat.comSG Americas Securities LLC Makes New Investment in Option Care Health, Inc. (NASDAQ:OPCH)June 21, 2025 | marketbeat.comRiverbridge Partners LLC Has $50.64 Million Stock Holdings in Option Care Health, Inc. (NASDAQ:OPCH)June 20, 2025 | marketbeat.comJanney Capital Management LLC Purchases New Position in Option Care Health, Inc. (NASDAQ:OPCH)June 20, 2025 | marketbeat.comOption Care Health (NASDAQ:OPCH) Earns "Market Outperform" Rating from JMP SecuritiesJune 20, 2025 | americanbankingnews.comOption Care Health, Inc. (NASDAQ:OPCH) Receives $35.50 Average Price Target from BrokeragesJune 20, 2025 | americanbankingnews.com1OPCH : Forecasting The Future: 5 Analyst Projections For Option Care HealthJune 18, 2025 | benzinga.comJMP Securities Reaffirms "Market Outperform" Rating for Option Care Health (NASDAQ:OPCH)June 18, 2025 | marketbeat.comOption Care Health, Inc. (NASDAQ:OPCH) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJune 17, 2025 | marketbeat.comAssenagon Asset Management S.A. Lowers Position in Option Care Health, Inc. (NASDAQ:OPCH)June 15, 2025 | marketbeat.comFort Washington Investment Advisors Inc. OH Trims Holdings in Option Care Health, Inc. (NASDAQ:OPCH)June 13, 2025 | marketbeat.comHere’s Why Option Care Health (OPCH) Surged in Q1June 12, 2025 | msn.comGAMMA Investing LLC Acquires 110,776 Shares of Option Care Health, Inc. (NASDAQ:OPCH)June 12, 2025 | marketbeat.comHarbor Capital Advisors Inc. Reduces Position in Option Care Health, Inc. (NASDAQ:OPCH)June 11, 2025 | marketbeat.comOption Care Health, Inc. (NASDAQ:OPCH) Shares Sold by Wedge Capital Management L L P NCJune 10, 2025 | marketbeat.com12,062 Shares in Option Care Health, Inc. (NASDAQ:OPCH) Acquired by Squarepoint Ops LLCJune 7, 2025 | marketbeat.comUnpacking Q1 Earnings: Option Care Health (NASDAQ:OPCH) In The Context Of Other Senior Health, Home Health & Hospice StocksJune 5, 2025 | msn.comTwo Sigma Investments LP Purchases 99,070 Shares of Option Care Health, Inc. (NASDAQ:OPCH)June 1, 2025 | marketbeat.com111 Capital Takes Position in Option Care Health, Inc. (NASDAQ:OPCH)May 31, 2025 | marketbeat.comJohn Hancock Small Cap Core Fund Q1 2025 CommentaryMay 30, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsAmong the Market’s Most Shorted: 2 Firms With +40% Short InterestBy Leo Miller | June 3, 2025View Among the Market’s Most Shorted: 2 Firms With +40% Short InterestPalantir Scores First $1 Billion Contract; Is It Priced In?By Chris Markoch | May 27, 2025View Palantir Scores First $1 Billion Contract; Is It Priced In?Why Super Micro Computer's Upside Could Trigger a Short SqueezeBy Gabriel Osorio-Mazilli | June 3, 2025View Why Super Micro Computer's Upside Could Trigger a Short SqueezeHIMS, NTRA, GH, and OPCH Company DescriptionsGuardant Health NASDAQ:GH$49.99 +1.44 (+2.97%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$50.24 +0.25 (+0.51%) As of 04:37 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.Hims & Hers Health NYSE:HIMS$42.98 +1.00 (+2.39%) Closing price 06/24/2025 03:59 PM EasternExtended Trading$43.28 +0.29 (+0.68%) As of 04:49 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.Natera NASDAQ:NTRA$171.87 +1.50 (+0.88%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$171.51 -0.36 (-0.21%) As of 06/24/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.Option Care Health NASDAQ:OPCH$32.26 +1.21 (+3.90%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$32.59 +0.33 (+1.02%) As of 04:25 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as multiple sclerosis, duchenne muscular dystrophy, and other neurological disorder; infusion therapies for bleeding disorders, such as hemophilia and von Willebrand diseases; therapies for women with high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services. The company markets its services through patient referrals, including physicians, hospital discharge planners, hospital personnel, health maintenance organizations, and preferred provider organizations. Option Care Health, Inc. is headquartered in Bannockburn, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs CrowdStrike Eyes Breakout as Cyber Threats Boost Demand Reddit Stock Ignites: Surge in Call Options Signals Big Bet Microsoft Stock Holds Steady as AI Drives Workforce Shift Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
